<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-ROM-2835</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2835</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group></article-categories><title-group><article-title>Роль морфогенных белков WNT-сигнального пути при ишемической болезни сердца</article-title><trans-title-group xml:lang="en"><trans-title>Role of morphogenic proteins of the WNT signaling pathway in coronary artery disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4258-963X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Снимщикова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Snimshchikova</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Снимщикова И.А. – д.м.н., профессор, заведующая кафедрой иммунологии и специализированных клинических дисциплин, директор Медицинского института </p><p>302026, г. Орел, ул. Комсомольская, 95.</p></bio><bio xml:lang="en"><p>Snimshchikova I.A., PhD, MD (Medicine), Professor, Head, Department of Immunology and Clinical Specialties, Director of the Medical Institute </p><p>95 Komsomolskaya St., Orel, 302026</p></bio><email xlink:type="simple">snimshikova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1593-5290</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Плотникова</surname><given-names>М. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Plotnikova</surname><given-names>M. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Плотникова М.О. – старший преподаватель кафедры иммунологии и специализированных клинических дисциплин Медицинского института </p><p>302026, г. Орел, ул. Комсомольская, 95.</p></bio><bio xml:lang="en"><p>Plotnikova M.O., Senior Lecturer, Department of Immunology and Clinical Specialties of the Medical Institute </p><p>95 Komsomolskaya St., Orel, 302026</p></bio><email xlink:type="simple">moplotnikova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Орловский государственный университет имени И.С. Тургенева»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Educational Institution of Higher Education "Orel State University named after I.S. Turgenev"</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>01</day><month>06</month><year>2023</year></pub-date><volume>25</volume><issue>4</issue><fpage>985</fpage><lpage>990</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Снимщикова И.А., Плотникова М.О., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Снимщикова И.А., Плотникова М.О.</copyright-holder><copyright-holder xml:lang="en">Snimshchikova I.A., Plotnikova M.O.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2835">https://www.mimmun.ru/mimmun/article/view/2835</self-uri><abstract><p>Исследования последних лет доказывают сложность патофизиологических процессов, участвующих в развитии острых форм ишемической болезни сердца и патологического ремоделирования миокарда. В последние годы внимание исследователей направлено на изучение WNT-сигнального пути, регулирующего процессы эмбриогенеза и участвующего в развитии патологических состояний. При этом роль морфогенных белков WNT-сигнального пути в генезе кардиоваскулярной патологии практически не выяснена. Целью исследования явилось комплексное изучение основных белков WNT-сигнального пути (β-катенина, склеростина, GSK-3α, GSK-3β, WIF-1 и DVL-1) сыворотки крови 353 больных острыми формами ишемической болезни сердца, находившихся на лечении в региональном сосудистом центре Орловской области с 2019 по 2021 гг., и 50 здоровых лиц. Комплексный анализ включал оценку клинико-лабораторных и инструментальных показателей в рамках действующих клинических рекомендаций, а также иммунологическое обследование по определению морфогенных белков WNT-сигналинга методом иммуноферментного анализа. Результаты исследований показали широкую вариабельность значений морфогенных белков WNT-сигнального пути в сыворотке крови больных. При этом уровень β-катенина, WIF-1 и DVL-1 значительно превышал аналогичные показатели, полученные у здоровых лиц, а концентрации склеростина и GSK-3β не имели с ними достоверных отличий. Наряду с этим уровень GSK-3α в сыворотке крови пациентов был в 2 раза ниже, чем у здоровых лиц. Максимально высокие концентрации склеростина были выявлены у пациентов с имеющимся кальцинозом створок аортального клапана и стенок аорты. Неблагоприятное течение острого коронарного синдрома наблюдалось у пациентов на фоне как крайне высоких, так и максимально низких показателей WIF-1 сыворотки крови. Установлены значимые корреляционные зависимости между уровнем морфогенных белков WNT-сигнального пути и показателями липидного обмена, а также ремоделирования миокарда. Полученные данные об изменении продукции агонистов и антагонистов WNT-сигнального пути позволяют расширить представления о молекулярных аспектах иммунопатогенеза миокардиального ремоделирования при ишемической болезни сердца, повышают предиктивный потенциал диагностики сердечно-сосудистых заболеваний и определяют вектор дальнейшего развития кардиоиммунологии. </p></abstract><trans-abstract xml:lang="en"><p>In recent years, researchers’ attention has been directed to the WNT signaling pathway study, which regulates embryogenesis processes and is involved in pathological condition development. The role of morphogenic proteins of WNT signaling pathway in the cardiovascular pathology genesis is practically not clear. The research aim was a comprehensive study of the main proteins of WNT signaling pathway (β-catenin, sclerostin, GSK-3α, GSK-3β, WIF-1 and DVL-1) in the blood serum of 353 patients with coronary artery disease acute forms who were treated at the Orel regional vascular center from 2019 to 2021, and 50 healthy individuals. A comprehensive analysis included an assessment of clinical, laboratory and instrumental parameters in the framework of current clinical guidelines, as well as an immunological examination to determine the morphogenic proteins of WNT signaling by enzyme immunoassay. The results showed a wide variability in the values of morphogenic proteins of WNT signaling pathway in the patient’s blood serum. The levels of β-catenin, WIF-1 and DVL-1 significantly exceeded those obtained in healthy individuals, while the concentrations of sclerostin and GSK-3β did not differ significantly from them. The level of GSK-3α of patients was twice lower than in healthy individuals. The highest sclerostin concentrations were found in patients with existing calcification of the aortic valve leaflets and aortic walls. Acute coronary syndrome unfavorable course was observed in patients with both extremely high and extremely low WIF-1 levels. Significant correlations were established between the level of morphogenic proteins of WNT signaling pathway and lipid metabolism, as well as myocardial remodeling. The obtained data on changes in the protein production of WNT signaling pathway allow us to expand our understanding of the molecular aspects of the immunopathogenesis of myocardial remodeling in coronary artery disease, increase the predictive potential for cardiovascular disease diagnosis and determine the vector for further development of cardioimmunology determination.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>WNT-сигнальный путь</kwd><kwd>β-катенин</kwd><kwd>склеростин</kwd><kwd>GSK3α</kwd><kwd>GSK3β</kwd><kwd>WIF-1</kwd><kwd>DVL-1</kwd><kwd>инфаркт миокарда</kwd><kwd>ишемическая болезнь сердца</kwd></kwd-group><kwd-group xml:lang="en"><kwd>WNT signaling pathway</kwd><kwd>β-catenin</kwd><kwd>sclerostin</kwd><kwd>GSK3α</kwd><kwd>GSK3β</kwd><kwd>WIF-1</kwd><kwd>DVL-1</kwd><kwd>myocardial infarction</kwd><kwd>coronary heart disease</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmad F., Woodgett J.R. Emerging roles of GSK-3α in pathophysiology: Emphasis on cardio-metabolic disorders. Biochim. Biophys. Acta Mol. Cell Res., 2020, Vol. 1867, no. 2, 118616. doi: 10.1016/j.bbamcr.2019.118616.</mixed-citation><mixed-citation xml:lang="en">Ahmad F., Woodgett J.R. Emerging roles of GSK-3α in pathophysiology: Emphasis on cardio-metabolic disorders. Biochim. Biophys. Acta Mol. Cell Res., 2020, Vol. 1867, no. 2, 118616. doi: 10.1016/j.bbamcr.2019.118616.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bravo-San Pedro J.M., Kroemer G., Galluzzi L. Autophagy and mitophagy in cardiovascular disease. Circ. Res., 2017, Vol. 120, no. 11, pp. 1812-1824.</mixed-citation><mixed-citation xml:lang="en">Bravo-San Pedro J.M., Kroemer G., Galluzzi L. Autophagy and mitophagy in cardiovascular disease. Circ. Res., 2017, Vol. 120, no. 11, pp. 1812-1824.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Förstermann U., Xia N., Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ. Res., 2017, Vol. 120, no. 4, pp. 713-735.</mixed-citation><mixed-citation xml:lang="en">Förstermann U., Xia N., Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ. Res., 2017, Vol. 120, no. 4, pp. 713-735.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Foulquier S., Daskalopoulos E.P., Lluri G., Hermans K.C.M., Deb A., Blankesteijn W.M. (2018). WNT signaling in cardiac and vascular disease. Pharmacol. Rev., Vol. 70, no. 1, pp. 68-141.</mixed-citation><mixed-citation xml:lang="en">Foulquier S., Daskalopoulos E.P., Lluri G., Hermans K.C.M., Deb A., Blankesteijn W.M. (2018). WNT signaling in cardiac and vascular disease. Pharmacol. Rev., Vol. 70, no. 1, pp. 68-141.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hernandez P., Whitty C., John Wardale R., Henson F.M. New insights into the location and form of sclerostin. Biochem. Biophys. Res. Commun., 2014, Vol. 446, no. 4, pp. 1108-1113.</mixed-citation><mixed-citation xml:lang="en">Hernandez P., Whitty C., John Wardale R., Henson F.M. New insights into the location and form of sclerostin. Biochem. Biophys. Res. Commun., 2014, Vol. 446, no. 4, pp. 1108-1113.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kulakova A.S., Snimshchikova I.A., Plotnikova M.O. Role of GSK-3 in Wnt/β-catenin signaling pathway in obesity. Medical Immunology (Russia), 2021, Vol. 23, no. 4, pp. 775-780. doi: 10.15789/1563-0625-ROG-2287.</mixed-citation><mixed-citation xml:lang="en">Kulakova A.S., Snimshchikova I.A., Plotnikova M.O. Role of GSK-3 in Wnt/β-catenin signaling pathway in obesity. Medical Immunology (Russia), 2021, Vol. 23, no. 4, pp. 775-780. doi: 10.15789/1563-0625-ROG-2287.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mermelstein C.S., Portilho D.M., Mendes F.A., Costa M.L., Abreu J.G. Wnt/beta-catenin pathway activation and myogenic differentiation are induced by cholesterol depletion. Differentiation, 2007, Vol. 75, no. 3, pp. 184-192.</mixed-citation><mixed-citation xml:lang="en">Mermelstein C.S., Portilho D.M., Mendes F.A., Costa M.L., Abreu J.G. Wnt/beta-catenin pathway activation and myogenic differentiation are induced by cholesterol depletion. Differentiation, 2007, Vol. 75, no. 3, pp. 184-192.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer I.S., Jungmann A., Dieterich C., Zhang M., Lasitschka F., Werkmeister S., Haas J., Müller O.J., Boutros M., Nahrendorf M., Katus H.A., Hardt S.E., Leuschner F. The cardiac microenvironment uses noncanonical WNT signaling to activate monocytes after myocardial infarction. EMBO Mol. Med., 2017, Vol. 9, no. 9, pp. 1279-1293.</mixed-citation><mixed-citation xml:lang="en">Meyer I.S., Jungmann A., Dieterich C., Zhang M., Lasitschka F., Werkmeister S., Haas J., Müller O.J., Boutros M., Nahrendorf M., Katus H.A., Hardt S.E., Leuschner F. The cardiac microenvironment uses noncanonical WNT signaling to activate monocytes after myocardial infarction. EMBO Mol. Med., 2017, Vol. 9, no. 9, pp. 1279-1293.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Roca C., Campillo N.E. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016-2019). Expert Opin. Ther. Pat., 2020, Vol. 30, no. 11, pp. 863-872.</mixed-citation><mixed-citation xml:lang="en">Roca C., Campillo N.E. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016-2019). Expert Opin. Ther. Pat., 2020, Vol. 30, no. 11, pp. 863-872.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Stylianidis V., Hermans K.C.M., Blankesteijn W.M. Wnt signaling in cardiac remodeling and heart failure. Handb. Exp. Pharmacol., 2017, Vol. 243, pp. 371-393.</mixed-citation><mixed-citation xml:lang="en">Stylianidis V., Hermans K.C.M., Blankesteijn W.M. Wnt signaling in cardiac remodeling and heart failure. Handb. Exp. Pharmacol., 2017, Vol. 243, pp. 371-393.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao H.D., Sun M.N., Li M.D., Li F.L., Li H. Dishevelled-1 (Dvl-1) protein: a potential participant of oxidative stress induced by selenium deficiency. Biol. Trace Elem. Res., 2014, Vol. 157, no. 1, pp. 45-50.</mixed-citation><mixed-citation xml:lang="en">Zhao H.D., Sun M.N., Li M.D., Li F.L., Li H. Dishevelled-1 (Dvl-1) protein: a potential participant of oxidative stress induced by selenium deficiency. Biol. Trace Elem. Res., 2014, Vol. 157, no. 1, pp. 45-50.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
